ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
BeOne Medicines Ltd.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$370.17+1.11 (+0.30%)
Close on Oct 19, 2026
- Market cap
- $557.24B
- P/E (TTM)
- 860.9
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
35M
Shares held, 13F filers
Institutional holders
283
46 new, 63 sold out
Net institutional buying
-2M
In Q2 2026
Insider trades, 12 months
0 buys · 198 sales
Net sold $368.78M
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| HHLR Advisors, Ltd. | 92,805,741 | 6.70% | 13D (active) amendment | Mar 3, 2025 |
| John V. Oyler | 71,464,808 | 5.20% | 13G (passive) amendment | Dec 31, 2023 |
| Felix J. Baker | 115,918,313 | 8.00% | 13D (active) amendment | Apr 16, 2026 |
| Julian C. Baker | 115,912,814 | 7.80% | 13D (active) amendment | Sep 14, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ONC | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Baker Bros. Advisors LP | 8,801,567 | – | $2.51B | +2,514 | 12.57% |
| Primecap Management Co/Ca/ | 5,007,931 | – | $1.43B | +32,750 | 0.84% |
| Capital International Investors | 4,210,221 | – | $1.20B | +51,495 | 0.25% |
| FMR LLC | 2,478,527 | – | $706.31M | −1,215,083 | 0.03% |
| Capital World Investors | 2,249,582 | – | $641.06M | +626,895 | 0.08% |
| Citadel Advisors LLC | 1,425,517 | – | $406.23M | +375,281 | 0.05% |
| Temasek Holdings (Private) Ltd | 845,729 | – | $241.01M | −16,914 | 0.65% |
| Price T Rowe Associates Inc /Md/ | 758,752 | – | $216.22K | +218,983 | 0.02% |
| BlackRock, Inc. | 694,618 | – | $197.95M | +34,117 | 0.00% |
| Millennium Management LLC | 543,323 | – | $154.83M | +338,477 | 0.06% |
| Morgan Stanley | 497,437 | – | $141.75M | +4,978 | 0.01% |
| Siren, L.L.C. | 465,000 | – | $132.51M | – | 2.68% |
| Bank Of America Corp /De/ | 439,336 | – | $125.20M | +34,063 | 0.01% |
| Baird Financial Group, Inc. | 368,978 | – | $105.15M | +19,327 | 0.14% |
| Man Group plc | 307,463 | – | $87.62M | +65,541 | 0.14% |
| Capital International, Inc./CA/ | 305,477 | – | $87.05M | +3,234 | 0.61% |
| Candriam S.C.A. | 289,735 | – | $82.49M | +30,004 | 0.37% |
| Two Sigma Investments, LP | 286,552 | – | $81.66M | +253,009 | 0.06% |
| UBS Group AG | 258,589 | – | $73.69M | −207,300 | 0.01% |
| Arrowstreet Capital, Limited Partnership | 249,758 | – | $71.17M | +139,172 | 0.03% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 283 | 35M | 46 / 110 | 84 / 63 | 3M | 6M |
| Q1 2026 | 307 | 38M | 42 / 117 | 88 / 49 | 6M | 4M |
| Q4 2025 | 318 | 37M | 67 / 117 | 75 / 36 | 2M | 2M |
| Q3 2025 | 292 | 36M | 60 / 102 | 80 / 42 | 3M | 3M |
| Q2 2025 | 274 | 36M | 31 / 96 | 89 / 53 | 1M | 9M |
| Q1 2025 | 297 | 44M | 71 / 99 | 79 / 26 | 6M | 7M |
| Q4 2024 | 256 | 45M | 40 / 88 | 80 / 33 | 3M | 6M |
| Q3 2024 | 252 | 48M | 57 / 53 | 96 / 26 | 4M | 3M |
| Q2 2024 | 223 | 48M | 23 / 77 | 71 / 23 | 1M | 2M |
| Q1 2024 | 225 | 49M | 42 / 97 | 46 / 43 | 4M | 5M |
| Q4 2023 | 229 | 51M | 48 / 58 | 76 / 29 | 2M | 5M |
| Q3 2023 | 215 | 54M | 21 / 75 | 67 / 30 | 7M | 2M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of ONC | Value | % of fund | As of |
|---|---|---|---|---|---|
| New Perspective Fund | 2,663,960 | – | $759.15M | 0.45% | Jun 30, 2026 |
| Vanguard Primecap Fund | 2,347,622 | – | $669.00M | 0.70% | Jun 30, 2026 |
| Vanguard Capital Opportunity Fund | 1,182,071 | – | $336.85M | 1.03% | Jun 30, 2026 |
| EUPAC Fund | 700,821 | – | $199.71M | 0.14% | Jun 30, 2026 |
| New World Fund Inc | 677,287 | – | $214.03M | 0.24% | Jul 31, 2026 |
| PRIMECAP Odyssey Aggressive Growth Fund | 646,087 | – | $204.17M | 2.76% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 624,896 | – | $179.92M | 0.18% | May 31, 2026 |
| PRIMECAP Odyssey Growth Fund | 585,087 | – | $184.89M | 3.05% | Jul 31, 2026 |
| iShares Biotechnology ETF | 564,180 | – | $160.77M | 1.77% | Jun 30, 2026 |
| New Economy Fund | 399,178 | – | $114.93M | 0.22% | May 31, 2026 |
| American Funds Global Insight Fund | 374,007 | – | $118.19M | 0.55% | Jul 31, 2026 |
| T. Rowe Price International Stock Fund | 261,437 | – | $82.62M | 0.62% | Jul 31, 2026 |
| First Trust NYSE Arca Biotechnology Index Fund | 245,095 | – | $69.84M | 2.48% | Jun 30, 2026 |
| Baird Chautauqua International Growth Fund | 179,205 | – | $51.07M | 3.91% | Jun 30, 2026 |
| Fidelity Growth Company K6 Fund | 174,859 | – | $50.35M | 0.18% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| John Oyler | Chief Executive Officer, Director | 7,815,448 | Aug 12, 2026 |
| Titus B. Ball | Principal Accounting Officer | 0 | Sep 3, 2026 |
| Xiaobin Wu | President and COO | 4,000 | Aug 27, 2026 |
| Chan Henry Lee | SVP, General Counsel | 812 | Aug 13, 2026 |
| Aaron Rosenberg | Chief Financial Officer | 0 | Aug 5, 2026 |
| Lai Wang | President, Global Head of R&D | 601,965 | Jun 25, 2026 |
| Xiaodong Wang | Director | 1,049,341 | Sep 30, 2026 |
| Bros. Advisors Lp Baker | Director | 922,957 | Sep 16, 2026 |
| Brothers Life Sciences LP Baker | Director | 8,229,958 | Sep 16, 2026 |
| Felix Baker | Director | 997,946 | Sep 16, 2026 |
| Bros. Advisors (GP) LLC Baker | Director | 730,643 | Sep 16, 2026 |
| 667, L.P. | Director | 10,803,789 | Sep 16, 2026 |
| Julian Baker | Director | 10,734,144 | Sep 16, 2026 |
| Elizabeth Fisher Mooney | Director | 18,980 | Jun 15, 2026 |
| Margaret Dugan | Director | 73,164 | Jun 15, 2026 |
| Anthony C. Hooper | Director | 83,720 | Jun 15, 2026 |
| Shalini Sharp | Director | 38,116 | Jun 15, 2026 |
| Olivier Brandicourt | Director | 46,306 | Jun 15, 2026 |
| Alessandro Riva | Director | 73,164 | Jun 15, 2026 |
| Charles Lazelle Sawyers | Director | 1,946 | Jun 15, 2026 |
| Qingqing Yi | Director | 0 | Jun 3, 2026 |
| Corazon (Corsee) D. Sanders | Director | 0 | May 27, 2026 |
| Hillhouse Investment Management, Ltd. | 10% owner | 125,045,741 | Dec 4, 2024 |
| Hhlr Advisors, Ltd. | 10% owner | 142,888,241 | Dec 4, 2024 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −4,239 | $362.17 | $1.54M | 24,228 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −14,525 | $366.58 | $5.32M | 738 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −2,047 | $365.85 | $748.89K | 15,263 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −3,419 | $364.07 | $1.24M | 17,310 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −3,499 | $363.10 | $1.27M | 20,729 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −738 | $367.23 | $271.02K | 0 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −2,241 | $361.05 | $809.11K | 28,467 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −40 | $359.16 | $14.37K | 30,708 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −120 | $358.71 | $43.05K | 30,748 |
| Xiaodong Wang Director | Sep 28, 2026 | Sale(10b5-1 plan) | −160 | $356.97 | $57.12K | 30,868 |
| Xiaodong Wang Director | Sep 28, 2026 | Option exercise | +31,028 | $36.90 | $1.14M | 31,028 |
| Bros. Advisors Lp Baker Director | Sep 14, 2026 | Option exercise | +30,768 | $36.83 | $1.13M | 761,410 |
| Bros. Advisors Lp Baker Director | Sep 14, 2026 | Option exercise | +30,768 | $36.83 | $1.13M | 8,099,179 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,278 | $351.25 | $2.21M | 0 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −2,841 | $346.16 | $983.44K | 3,238 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,517 | $347.39 | $526.99K | 1,721 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,721 | $348.01 | $598.93K | 0 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −6,569 | $350.27 | $2.30M | 6,278 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −1,181 | $345.38 | $407.89K | 6,079 |
| Xiaodong Wang Director | Sep 8, 2026 | Option exercise | +31,027 | $36.90 | $1.14M | 31,027 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −7,492 | $348.31 | $2.61M | 23,535 |
| Xiaodong Wang Director | Sep 8, 2026 | Sale(10b5-1 plan) | −10,688 | $349.28 | $3.73M | 12,847 |
| Titus B. Ball Principal Accounting Officer | Sep 1, 2026 | Sale | −132 | $355.86 | $46.97K | 0 |
| Xiaobin Wu President and COO | Aug 25, 2026 | Sale(10b5-1 plan) | −280 | $380.00 | $106.40K | 0 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −20,899 | $358.41 | $7.49M | 14,102 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −15,396 | $357.63 | $5.51M | 35,001 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −2,515 | $356.43 | $896.42K | 50,397 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −1,980 | $354.71 | $702.33K | 52,912 |
| John Oyler Chief Executive Officer, Director | Aug 12, 2026 | Sale(10b5-1 plan) | −14,102 | $359.12 | $5.06M | 0 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Option exercise | +812 | $194.47 | $157.91K | 812 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Option exercise | +1,058 | $213.32 | $225.69K | 1,870 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Option exercise | +796 | $159.03 | $126.59K | 2,666 |
| Chan Henry Lee SVP, General Counsel | Aug 11, 2026 | Sale(10b5-1 plan) | −2,666 | $360.00 | $959.76K | 0 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −4 | $367.00 | $1.47K | 54,892 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −1,200 | $366.31 | $439.57K | 54,896 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −3,176 | $365.26 | $1.16M | 56,096 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −5,211 | $364.31 | $1.90M | 59,272 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −13,403 | $363.45 | $4.87M | 64,483 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −11,568 | $362.34 | $4.19M | 77,886 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −14,569 | $361.47 | $5.27M | 89,454 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −8,081 | $360.33 | $2.91M | 104,023 |
| John Oyler Chief Executive Officer, Director | Aug 11, 2026 | Sale(10b5-1 plan) | −13,695 | $359.32 | $4.92M | 112,104 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −2,813 | $351.80 | $989.61K | 237,930 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −3,680 | $360.63 | $1.33M | 125,799 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −21,254 | $359.50 | $7.64M | 129,479 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −45,044 | $358.70 | $16.16M | 150,733 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −15,869 | $357.67 | $5.68M | 195,777 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −12,418 | $356.62 | $4.43M | 211,646 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −3,476 | $355.66 | $1.24M | 224,064 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −6,717 | $354.78 | $2.38M | 227,540 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −3,673 | $353.32 | $1.30M | 234,257 |
| John Oyler Chief Executive Officer, Director | Aug 10, 2026 | Sale(10b5-1 plan) | −67 | $350.00 | $23.45K | 240,743 |
| Aaron Rosenberg Chief Financial Officer | Aug 3, 2026 | Sale | −1,157 | $312.72 | $361.82K | 0 |
| Chan Henry Lee SVP, General Counsel | Jul 30, 2026 | Sale | −1,044 | $323.69 | $337.93K | 0 |
| Chan Henry Lee SVP, General Counsel | Jul 22, 2026 | Option exercise | +514 | $194.47 | $99.96K | 514 |
| Chan Henry Lee SVP, General Counsel | Jul 22, 2026 | Option exercise | +665 | $213.32 | $141.86K | 1,179 |
| Chan Henry Lee SVP, General Counsel | Jul 22, 2026 | Option exercise | +490 | $159.03 | $77.92K | 1,669 |
| Chan Henry Lee SVP, General Counsel | Jul 22, 2026 | Sale(10b5-1 plan) | −1,669 | $325.00 | $542.43K | 0 |
| John Oyler Chief Executive Officer, Director | Jul 21, 2026 | Sale(10b5-1 plan) | −2,340 | $320.06 | $748.94K | 0 |
| John Oyler Chief Executive Officer, Director | Jul 21, 2026 | Sale(10b5-1 plan) | −15,807 | $319.29 | $5.05M | 2,340 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Lee Chan Officer | Sep 30, 2026 | 1,115 | $407.28K | Sep 30, 2026 | Restricted Stock Units |
| Wang Xiaodong Director, Chair, Scientific Advisory Brd | Sep 8, 2026 | 131,370 | $47.06M | Sep 8, 2026 | Exercise of Stock Options |
| Benjamin Ball Titus Officer | Sep 1, 2026 | 132 | $46.97K | Sep 1, 2026 | Restricted Stock Vesting Under a Registered Plan |
| D. Sanders Corazon Former Director | Aug 25, 2026 | 2,075 | $788.50K | Aug 25, 2026 | Exercise of Options Under a Registered Plan |
| Wu Xiaobin Officer | Aug 25, 2026 | 15,000 | $5.58M | Aug 25, 2026 | Restricted Stock Units |
| Lee Chan Officer | Aug 11, 2026 | 2,002 | $718.72K | Aug 11, 2026 | Exercise of Stock Options |
| V. Oyler John Director, Officer | Aug 10, 2026 | 240,810 | $83.87M | Aug 10, 2026 | Previously Exercised Stock Options |
| Rosenberg Aaron Officer | Aug 3, 2026 | 1,157 | $361.81K | Aug 3, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Lee Chan Officer | Jul 30, 2026 | 1,044 | $337.93K | Jul 30, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Lee Chan Officer | Jul 22, 2026 | 2,001 | $637.69K | Jul 22, 2026 | Exercise of Stock Options |
| V. Oyler John Director, Officer | Jul 14, 2026 | 513,574 | $156.11M | Jul 14, 2026 | Exercise of Stock Options |
| Foundation Pan-Oyler Director, Officer | Jul 10, 2026 | 49,541 | $15.00M | Jul 10, 2026 | Founders Shares |
| V. Oyler John Director, Officer | Jul 10, 2026 | 150,000 | $45.42M | Jul 10, 2026 | Exercise of Stock Options |
| Oyler John Officer, Director | Jun 23, 2026 | 3,410 | $933.59K | Jun 23, 2026 | Restricted Stock Vesting Under a Registered Plan |
| Wu Xiaobin Officer | Jun 23, 2026 | 1,292 | $356.93K | Jun 23, 2026 | Restricted Stock Vesting Under a Registered Plan |